CD47/SIRPA-BLOCKING AGENT ALX148
Indolent B-Cell Non-Hodgkin Lymphoma
Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
protein_peptide
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05025800CT.gov ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Indolent B-Cell Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| CD47/SIRPA-BLOCKING AGENT ALX148 (this asset) | M.D. Anderson Cancer Center | P1/2 | CC · 47 |
| Cyclophosphamide | Institute of Hematology & Blood Diseases Hospital, China | P2 | BB |
| Fludarabine | Institute of Hematology & Blood Diseases Hospital, China | P3 | BB |
| Pembrolizumab | University of Washington | P2 | BB |
| Rituximab | Fox Chase Cancer Center | P3 | BB |
| Vaccin Genhevac B Pasteur | Central Hospital, Nancy, France | P4 | BB |
| Ibrutinib | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P3 | BB |
| Lenalidomide | Antengene Corporation | P2 | BB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BB |
+42 more in the Indolent B-Cell Non-Hodgkin Lymphoma cohort
Other indications for CD47/SIRPA-BLOCKING AGENT ALX148
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P2 | B · 60 |
| Plasma Cell Myeloma | — | P1/2 | CCC · 48 |
| Composite Lymphoma | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. CD47/SIRPA-BLOCKING AGENT ALX148 in Indolent B-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/cd47sirpa-blocking-agent-alx148-indolent-b-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →